135 related articles for article (PubMed ID: 10536419)
21. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
22. [The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Czygier M; Szmitkowski M
Przegl Lek; 2007; 64(12):987-90. PubMed ID: 18595499
[TBL] [Abstract][Full Text] [Related]
23. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
24. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
25. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
26. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
[TBL] [Abstract][Full Text] [Related]
27. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
28. Increased levels of serum macrophage colony-stimulating factor before the onset of preeclampsia.
Hayashi M; Ohkura T; Inaba N
Horm Metab Res; 2003 Oct; 35(10):588-92. PubMed ID: 14605992
[TBL] [Abstract][Full Text] [Related]
29. Macrophage migration inhibitory factor expression in ovarian cancer.
Agarwal R; Whang DH; Alvero AB; Visintin I; Lai Y; Segal EA; Schwartz P; Ward D; Rutherford T; Mor G
Am J Obstet Gynecol; 2007 Apr; 196(4):348.e1-5. PubMed ID: 17403417
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of macrophage-colony stimulating factor (M-CSF): a marker of kidney allograft rejection.
Le Meur Y; Leprivey-Lorgeot V; Mons S; José M; Dantal J; Lemauff B; Aldigier JC; Leroux-Robert C; Praloran V
Nephrol Dial Transplant; 2004 Jul; 19(7):1862-5. PubMed ID: 15150350
[TBL] [Abstract][Full Text] [Related]
31. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
Elg S; Halberg E; Ramakrishnan S; Cornélissen G; Haus E; Nicolau G; Carson L; Twiggs L; Long HJ; Halberg F
Chronobiologia; 1991; 18(4):141-52. PubMed ID: 1687728
[TBL] [Abstract][Full Text] [Related]
32. Circulating macrophage colony stimulating factor as a marker of tumour progression.
McDermott RS; Deneux L; Mosseri V; Védrenne J; Clough K; Fourquet A; Rodriguez J; Cosset JM; Sastre X; Beuzeboc P; Pouillart P; Scholl SM
Eur Cytokine Netw; 2002; 13(1):121-7. PubMed ID: 11956031
[TBL] [Abstract][Full Text] [Related]
33. Elevated levels of macrophage colony-stimulating factor in human fracture healing.
Sarahrudi K; Mousavi M; Thomas A; Eipeldauer S; Vécsei V; Pietschmann P; Aharinejad S
J Orthop Res; 2010 May; 28(5):671-6. PubMed ID: 19950360
[TBL] [Abstract][Full Text] [Related]
34. Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
Hayashi M; Shibazaki M; Sohma R; Inaba N
Am J Med Sci; 2006 Oct; 332(4):181-5. PubMed ID: 17031243
[TBL] [Abstract][Full Text] [Related]
35. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
[TBL] [Abstract][Full Text] [Related]
37. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].
Xu KF; Chen Y; Guo ZJ; Zhu YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782
[TBL] [Abstract][Full Text] [Related]
38. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
39. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I
Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105
[TBL] [Abstract][Full Text] [Related]
40. [Serum levels of macrophage colony stimulating factor in the patients with Alzheimer's disease].
Kong QL; Zhang JM; Zhang ZX; Ge PJ; Xu YJ; Mi RS; Zhao YH; Sui YP; He W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):298-301. PubMed ID: 12905639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]